Skip Navigation LinksHome > April 2010 - Volume 22 - Issue 4 > Synergistic antifibrotic effect of verapamil and interferon-...
European Journal of Gastroenterology & Hepatology:
doi: 10.1097/MEG.0b013e32833226d5
Original Articles: Liver Fibrosis and Cirrhosis

Synergistic antifibrotic effect of verapamil and interferon-γ in rats: partially based on enhanced verapamil oral bioavailability

Xu, Dana; Chen, Mana; Guo, Yua; Liang, Gaia; Zhang, Benjiana; Tan, Jingquanb; Magdalou, Jacquesc; Wang, Huia b

Collapse Box

Abstract

Objective: The objective of this study was to investigate the synergistic antifibrotic effect of verapamil and interferon-γ (IFN-γ) on rat liver fibrosis and its potential pharmacokinetic-based mechanism.

Methods: Rat liver fibrosis model was successfully established, and both the therapeutic effects and pharmacokinetic parameters of verapamil were evaluated after the administration of verapamil with or without IFN-γ. The activities of cytochrome P450 3A (CYP3A) and the expression of multidrug resistance (Mdr) mRNA were measured in liver and small intestine.

Results: The results showed the synergistic antifibrotic effect of verapamil and IFN-γ in rat liver fibrosis, in terms of decreased serum L-alanine aminotransferase activity and liver hydroxyproline content and improved liver histopathology, when compared with rats treated with verapamil or IFN-γ alone. Meanwhile, the area under the curve of verapamil increased significantly after single administration of verapamil and IFN-γ and the concentration of verapamil in plasma increased, but the metabolite : parent ratio of verapamil decreased after consecutive administrations of verapamil and IFN-γ. Furthermore, the activities of CYP3A in both the liver and the small intestine and the expression of Mdr in small intestine decreased in rats treated with verapamil and IFN-γ.

Conclusion: All these results indicated that the combination of verapamil and IFN-γ exerts a synergistic antifibrotic effect on rat liver fibrosis. The mechanism was partially based on the enhanced oral bioavailability of verapamil by increasing the intestinal absorption as well as reducing the first-pass metabolism, through inhibition of CYP3A activity and P-glycoprotein expression by IFN-γ.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.